See more : Changan Minsheng APLL Logistics Co., Ltd. (1292.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Nissui Pharmaceutical Co., Ltd. (4550.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nissui Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- APA Group (APAJF) Income Statement Analysis – Financial Results
- Top Education Group Ltd (1752.HK) Income Statement Analysis – Financial Results
- Knight Club Capital Asset Management Public Company Limited (KCC.BK) Income Statement Analysis – Financial Results
- Avistar Communications Corporation (AVSR) Income Statement Analysis – Financial Results
- Bumrungrad Hospital Public Company Limited (BZ7A.F) Income Statement Analysis – Financial Results
Nissui Pharmaceutical Co., Ltd. (4550.T)
About Nissui Pharmaceutical Co., Ltd.
Nissui Pharmaceutical Co., Ltd. produces, sells, imports, and exports culture media and diagnostics for medical institutions, research organizations, and food industries in Japan and internationally. It offers in vitro diagnostics and medical devices; culture media for microbiological testing; products for antimicrobial susceptibility tests, microorganism identification, and immunological tests; and quality control serum, which is used for ensuring the accuracy of clinical diagnoses. In addition,, the company provides microbiological testing products for food poisoning detection; immunosorbent assays for the detection of allergies to food items, such as eggs, wheat, milk, shrimp, crabs, buckwheat, peanuts, etc.; and culture media and reagents for regenerative medicine. Further, it supplies testing agents and bulk products to diagnostic agent manufacturers; and CompactDry, a dry medium that is used for coliform counting for food manufacturers. The company was formerly known as Nissan Research Institute Co., Ltd. and changed its name to Nissui Pharmaceutical Co., Ltd. in 1962. Nissui Pharmaceutical Co., Ltd. was founded in 1935 and is headquartered in Tokyo, Japan.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.66B | 12.38B | 12.77B | 12.55B | 12.33B | 12.83B | 12.02B | 11.86B | 13.14B | 13.19B | 13.39B | 13.28B | 12.47B | 14.40B | 14.52B |
| Cost of Revenue | 11.40B | 8.19B | 7.05B | 6.79B | 6.48B | 6.44B | 5.85B | 5.93B | 6.24B | 6.28B | 6.50B | 6.51B | 6.36B | 7.39B | 7.20B |
| Gross Profit | 5.26B | 4.20B | 5.73B | 5.76B | 5.85B | 6.38B | 6.17B | 5.93B | 6.90B | 6.91B | 6.89B | 6.78B | 6.11B | 7.01B | 7.32B |
| Gross Profit Ratio | 31.57% | 33.90% | 44.83% | 45.88% | 47.47% | 49.77% | 51.34% | 50.02% | 52.50% | 52.42% | 51.45% | 51.02% | 49.02% | 48.65% | 50.41% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 635.87M | 535.11M | 509.66M | 541.45M | 620.01M | 685.40M | 754.85M | 749.76M | 877.05M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 735.97M | 707.71M | 705.85M | 733.23M | 765.78M | 506.79M | 494.39M | 716.27M | 737.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 513.27M | 582.58M | 678.12M | 691.95M | 702.32M | 708.53M | 624.23M | 861.30M | 935.73M |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.25B | 1.29B | 1.38B | 1.43B | 1.47B | 1.22B | 1.12B | 1.58B | 1.67B |
| Other Expenses | 3.69B | 3.40B | 4.58B | 4.45B | 4.43B | 4.69B | 1.47B | 1.47B | 1.42B | 1.49B | 1.59B | 1.84B | 1.80B | 2.08B | 2.15B |
| Operating Expenses | 3.69B | 3.40B | 4.58B | 4.45B | 4.43B | 4.69B | 3.35B | 3.30B | 3.31B | 3.46B | 3.68B | 3.74B | 3.68B | 4.41B | 4.70B |
| Cost & Expenses | 15.09B | 11.59B | 11.63B | 11.24B | 10.90B | 11.13B | 9.20B | 9.23B | 9.56B | 9.74B | 10.18B | 10.25B | 10.03B | 11.81B | 11.90B |
| Interest Income | 71.00M | 71.00M | 65.00M | 41.00M | 37.00M | 33.21M | 43.12M | 73.79M | 95.07M | 78.91M | 102.08M | 121.26M | 122.90M | 115.31M | 138.43M |
| Interest Expense | 71.00M | 0.00 | 0.00 | 0.00 | 0.00 | 37.00K | 112.00K | 94.00K | 92.00K | 105.00K | 136.00K | 1.14M | 1.06M | 2.10M | 231.00K |
| Depreciation & Amortization | 236.00M | 286.00M | 365.00M | 380.00M | 388.00M | 405.04M | 340.56M | 323.34M | 350.51M | 366.38M | 481.13M | 581.46M | 585.50M | 572.52M | 482.19M |
| EBITDA | 1.96B | 1.22B | 1.01B | 1.76B | 2.08B | 2.99B | 3.26B | 4.04B | 3.99B | 3.65B | 3.29B | 2.67B | 2.26B | 1.41B | 1.85B |
| EBITDA Ratio | 11.74% | 9.84% | 7.88% | 14.03% | 16.85% | 23.31% | 27.11% | 34.09% | 30.40% | 27.64% | 24.53% | 20.12% | 18.14% | 9.81% | 12.73% |
| Operating Income | 1.72B | 793.00M | 1.15B | 1.31B | 1.43B | 1.70B | 2.82B | 2.64B | 3.59B | 3.45B | 3.21B | 3.04B | 2.43B | 2.60B | 2.62B |
| Operating Income Ratio | 10.33% | 6.40% | 8.96% | 10.46% | 11.58% | 13.24% | 23.43% | 22.22% | 27.29% | 26.18% | 23.97% | 22.86% | 19.52% | 18.02% | 18.05% |
| Total Other Income/Expenses | -71.00M | 139.00M | -503.00M | 69.00M | 263.00M | 886.15M | 101.23M | 1.08B | 57.76M | -173.91M | -405.82M | -946.53M | -758.18M | -1.76B | -1.25B |
| Income Before Tax | 1.65B | 932.00M | 642.00M | 1.38B | 1.69B | 2.58B | 2.92B | 3.72B | 3.64B | 3.28B | 2.80B | 2.09B | 1.68B | 837.76M | 1.37B |
| Income Before Tax Ratio | 9.90% | 7.53% | 5.03% | 11.01% | 13.72% | 20.15% | 24.27% | 31.36% | 27.73% | 24.86% | 20.94% | 15.74% | 13.44% | 5.82% | 9.41% |
| Income Tax Expense | 503.00M | 284.00M | 240.00M | 597.00M | 515.00M | 681.05M | 875.26M | 1.25B | 1.34B | 1.05B | 1.19B | 818.08M | 755.13M | 388.50M | 570.91M |
| Net Income | 21.23B | 648.00M | 401.00M | 784.00M | 1.18B | 1.90B | 2.04B | 2.47B | 2.31B | 2.23B | 1.62B | 1.27B | 920.57M | 449.26M | 794.52M |
| Net Income Ratio | 6.88% | 5.23% | 3.14% | 6.25% | 9.53% | 14.84% | 16.99% | 20.83% | 17.55% | 16.92% | 12.07% | 9.58% | 7.38% | 3.12% | 5.47% |
| EPS | 68.22 | 2.08 | 1.29 | 2.52 | 130.56M | 211.43M | 226.79M | 274.55M | 256.19M | 248.00M | 179.54M | 141.35M | 102.29M | 49.92M | 88.28M |
| EPS Diluted | 68.22 | 2.08 | 1.29 | 2.52 | 130.56M | 211.43M | 226.79M | 274.55M | 256.19M | 248.00M | 179.54M | 141.35M | 102.29M | 49.92M | 88.28M |
| Weighted Avg Shares Out | 311.24M | 311.21M | 311.21M | 311.39M | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 |
| Weighted Avg Shares Out (Dil) | 311.24M | 311.21M | 311.21M | 311.39M | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 |
Source: https://incomestatements.info
Category: Stock Reports